このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Low-Dose Rocuronium Maintenance During Spine Surgery With Intraoperative Neurophysiological Monitoring (ROC-IONM)

2026年5月30日 更新者:Nguyen Toan Thang、Bach Mai Hospital

A Randomized Controlled Trial Comparing Low-Dose Rocuronium Maintenance Versus Discontinuation After Induction on Motor Evoked Potential Quality During Spine Surgery With Intraoperative Neurophysiological Monitoring

This randomized controlled trial will compare two strategies for rocuronium use during general anesthesia for spine surgery with intraoperative neurophysiological monitoring. Participants undergoing spine surgery under general anesthesia with motor evoked potential and/or somatosensory evoked potential monitoring will be randomized to either low-dose rocuronium maintenance targeting a train-of-four ratio of 0.60 to less than 0.90, or no rocuronium maintenance after induction.

The main objective is to compare the effects of these two strategies on the quality of intraoperative neurophysiological monitoring, especially motor evoked potential signals. Secondary objectives include comparing surgical field conditions, unwanted patient movement, emergence and extubation times, early respiratory events, and new postoperative neurological deficits.

The study will be conducted at the Center for Anesthesia and Surgical Intensive Care, Bach Mai Hospital, Hanoi, Vietnam. The planned sample size is 62 participants, with 31 participants in each group.

調査の概要

詳細な説明

Intraoperative neurophysiological monitoring is commonly used during complex spine surgery to help detect early neurological injury. Motor evoked potentials are particularly sensitive to neuromuscular blockade. Avoiding maintenance neuromuscular blockade may improve motor evoked potential signal quality, but may increase the risk of unwanted patient movement and suboptimal surgical field conditions. Conversely, low-dose rocuronium maintenance may improve surgical conditions, but may reduce motor evoked potential amplitude if neuromuscular blockade is excessive.

This trial will evaluate whether low-dose rocuronium maintenance, titrated by quantitative neuromuscular monitoring, can preserve intraoperative neurophysiological monitoring quality while improving surgical field conditions compared with discontinuation of rocuronium after induction.

All participants will receive standardized total intravenous anesthesia with propofol-based maintenance, bispectral index monitoring, quantitative train-of-four monitoring, and intraoperative neurophysiological monitoring. Rocuronium will be administered for tracheal intubation in both groups. In the low-dose maintenance group, rocuronium will be titrated to maintain a train-of-four ratio from 0.60 to less than 0.90. In the no-maintenance group, no additional rocuronium will be given after induction unless predefined safety rescue is required.

The primary outcome will be intraoperative motor evoked potential signal quality, including mean motor evoked potential amplitude. Secondary outcomes will include successful motor evoked potential recording, motor evoked potential warning events, somatosensory evoked potential stability, surgical field condition, unwanted patient movement, time to emergence, time to extubation, early postoperative respiratory events, and new postoperative neurological deficits.

研究の種類

介入

入学 (推定)

62

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Duc Minh Tran, MD
  • 電話番号:84589916666 84869319291
  • メール:tdminh1312@gmail.com

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

- 1. Patients aged 18 years or older. 2. Patients scheduled for spine surgery under general anesthesia. 3. Patients undergoing spine surgery with intraoperative neurophysiological monitoring, including motor evoked potentials and/or somatosensory evoked potentials.

4. Patients who agree to participate in the study and provide written informed consent.

Exclusion Criteria:

  • 1. Pre-existing central or peripheral neurological disease that may affect intraoperative neurophysiological monitoring, such as quadriplegia, persistent sensory disorder, sequelae of stroke, or polyneuropathy.

    2. History of epilepsy or electroencephalographic disorder. 3. Use of neuropsychiatric drugs, strong sedatives, or drugs affecting neuromuscular or neurological conduction within 48 hours before surgery.

    4. Decompensated cardiovascular disease or severe respiratory disease that may affect emergence or anesthetic drug metabolism.

    5. Contraindication to intraoperative neurophysiological monitoring. 6. Contraindication to rocuronium. 7. Refusal to participate or withdrawal of consent at any time..

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Low-Dose Rocuronium Maintenance
Participants in this group will receive rocuronium for tracheal intubation followed by low-dose rocuronium maintenance during surgery. Rocuronium will be titrated using quantitative train-of-four monitoring to maintain a train-of-four ratio from 0.60 to less than 0.90. All participants will receive standardized total intravenous anesthesia and intraoperative neurophysiological monitoring.
Rocuronium will be administered for tracheal intubation and then maintained at a low dose during surgery. The infusion will be titrated according to quantitative train-of-four monitoring to maintain a train-of-four ratio from 0.60 to less than 0.90.
アクティブコンパレータ:No Rocuronium Maintenance After Induction
Participants in this group will receive rocuronium for tracheal intubation only. No maintenance rocuronium will be administered after induction. Additional rocuronium may be given only as predefined safety rescue if clinically necessary. All participants will receive standardized total intravenous anesthesia and intraoperative neurophysiological monitoring.
Rocuronium will be administered only for tracheal intubation during induction of anesthesia. No maintenance rocuronium will be administered after induction, except for predefined safety rescue if clinically necessary.
他の名前:
  • Rocuronium for Intubation Only

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Mean Intraoperative Motor Evoked Potential Amplitude
時間枠:From baseline intraoperative neurophysiological monitoring after patient positioning to the final intraoperative neurophysiological monitoring recording before wound closure
Mean intraoperative motor evoked potential amplitude, measured in microvolts, recorded from predefined target muscles during spine surgery. The mean of three consecutive technically acceptable responses will be used at standardized intraoperative time points after stabilization of anesthesia and physiologic parameters.
From baseline intraoperative neurophysiological monitoring after patient positioning to the final intraoperative neurophysiological monitoring recording before wound closure

二次結果の測定

結果測定
メジャーの説明
時間枠
Successful Motor Evoked Potential Recording
時間枠:During surgery
Proportion of participants with successful intraoperative motor evoked potential recording from at least one predefined target muscle.
During surgery
Motor Evoked Potential Warning Events
時間枠:During surgery
Number of intraoperative motor evoked potential warning events, defined as a decrease of 50 percent or more in amplitude from baseline lasting more than 5 minutes and not attributable to surgical manipulation after correction of physiologic and technical factors.
During surgery
Surgical Field Condition
時間枠:During surgery
Surgical field condition assessed using the Leiden-Surgical Rating Scale, ranging from 1 to 5, with higher scores indicating better surgical conditions.
During surgery
Unwanted Patient Movement
時間枠:During surgery
Occurrence and number of unwanted patient movement events that affect surgical manipulation or require anesthetic or neuromuscular blockade adjustment.
During surgery
Time to Extubation
時間枠:From discontinuation of maintenance anesthesia to tracheal extubation
Time from discontinuation of maintenance anesthetic infusion to safe tracheal extubation, measured in minutes.
From discontinuation of maintenance anesthesia to tracheal extubation
New Postoperative Neurological Deficit
時間枠:Post-anesthesia care unit and 24 to 48 hours after surgery
Occurrence of new postoperative motor or sensory neurological deficit assessed in the post-anesthesia care unit and within 24 to 48 hours after surgery.
Post-anesthesia care unit and 24 to 48 hours after surgery
Somatosensory Evoked Potential Stability
時間枠:During surgery
Proportion of intraoperative monitoring time without significant somatosensory evoked potential changes, defined as latency increase of 10 percent or more or amplitude decrease of 50 percent or more from baseline lasting more than 5 minutes and not attributable to surgical manipulation.
During surgery
Time to Emergence
時間枠:From discontinuation of maintenance anesthesia to eye opening on verbal command
Time from discontinuation of maintenance anesthetic infusion to eye opening on verbal command, measured in minutes.
From discontinuation of maintenance anesthesia to eye opening on verbal command
Early Postoperative Respiratory Events
時間枠:During emergence and within 60 minutes after arrival in the post-anesthesia care unit
Occurrence of early respiratory events, including oxygen desaturation below 92 percent, laryngospasm, bronchospasm, sputum obstruction, or delayed extubation due to respiratory muscle weakness.
During emergence and within 60 minutes after arrival in the post-anesthesia care unit

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Toan Thang Nguyen, MD, PhD, Associate Professor、Hanoi Medical University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年6月1日

一次修了 (推定)

2028年12月1日

研究の完了 (推定)

2028年12月1日

試験登録日

最初に提出

2026年5月30日

QC基準を満たした最初の提出物

2026年5月30日

最初の投稿 (実際)

2026年6月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月4日

QC基準を満たした最後の更新が送信されました

2026年5月30日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • HMU-BMH-ROC-IONM-2025-01
  • 225/BM-HDDD (その他の識別子:Ethics Committee of Bach Mai Hospital)
  • 6513/QD-DHYHN (その他の識別子:Hanoi Medical University)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be publicly shared because the study involves sensitive clinical and perioperative data. Data are protected by privacy and ethical restrictions. De-identified aggregate data may be available from the corresponding author upon reasonable request and with approval from the relevant ethics committee.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する